WeVote
Log In

Bill

Bill

SB 1213

Enacts requirements for certain reporting regarding the federal 340B drug program

2026 Regular Session Introduced by Joe Nicola

Missouri requires 340B drug program participants to report program activity details to state authorities for transparency and oversight purposes.

Hearing Conducted S Families, Seniors and Health Committee
0
WeVote Research Nonpartisan
Bill Summary · SB 1213

Legislative bill overview

SB 1213 requires certain entities participating in the federal 340B drug program to report specified information to Missouri state authorities. The 340B program allows hospitals, clinics, and other healthcare providers to purchase medications at significant discounts from pharmaceutical manufacturers. This bill adds state-level transparency and oversight requirements to that federal program.

Why is this important

The 340B program affects drug pricing and accessibility across Missouri's healthcare system. State reporting requirements could improve transparency about how discounts are used, help identify potential program misuse, or create administrative burden depending on implementation details. Understanding local 340B utilization helps policymakers evaluate whether the program achieves its intended goals of reducing medication costs for underserved populations.

Potential points of contention

  • Federal-state coordination: The bill creates state reporting requirements for a federally-regulated program, potentially creating duplicative or conflicting oversight
  • Administrative burden: Healthcare providers may argue reporting requirements increase operational costs without clear public benefit
  • Data specificity unclear: Without seeing the bill text, the scope of required reporting is unknown—broad requirements could expose proprietary business information or narrow requirements may provide limited value

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.